BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30142016)

  • 1. Serial Endoscopic Evaluation of Esophageal Disease in a Cancer Model: A Paradigm Shift for Esophageal Adenocarcinoma (EAC) Drug Discovery and Development.
    Omstead AN; Kosovec JE; Matsui D; Martin SA; Smith MA; Aaron Guel D; Kolano J; Komatsu Y; Habib F; Lai C; Christopher K; Kelly RJ; Zaidi AH; Jobe BA
    Cancer Invest; 2018; 36(7):363-370. PubMed ID: 30142016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal Model: Reflux Models in Esophageal Adenocarcinoma.
    Masuda T; Mittal SK
    Methods Mol Biol; 2018; 1756():143-150. PubMed ID: 29600367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High yield reproducible rat model recapitulating human Barrett's carcinogenesis.
    Matsui D; Omstead AN; Kosovec JE; Komatsu Y; Lloyd EJ; Raphael H; Kelly RJ; Zaidi AH; Jobe BA
    World J Gastroenterol; 2017 Sep; 23(33):6077-6087. PubMed ID: 28970723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.
    Kestens C; Leenders M; Offerhaus GJ; van Baal JW; Siersema PD
    Endoscopy; 2015 May; 47(5):409-14. PubMed ID: 25521571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors in the development of esophageal adenocarcinoma.
    Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
    Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical biology of the Barrett's metaplasia, dysplasia to carcinoma sequence.
    DeMeester TR
    Surg Oncol; 2001 Nov; 10(3):91-102. PubMed ID: 11750228
    [No Abstract]   [Full Text] [Related]  

  • 9. Rat Reflux Model of Esophageal Cancer and Its Implication in Human Disease.
    Greene CL; Worrell SG; DeMeester TR
    Ann Surg; 2015 Dec; 262(6):910-24. PubMed ID: 25822684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From reflux esophagitis to Barrett's esophagus and esophageal adenocarcinoma.
    Wang RH
    World J Gastroenterol; 2015 May; 21(17):5210-9. PubMed ID: 25954094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen.
    Goldstein SR; Yang GY; Curtis SK; Reuhl KR; Liu BC; Mirvish SS; Newmark HL; Yang CS
    Carcinogenesis; 1997 Nov; 18(11):2265-70. PubMed ID: 9395230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroesophageal reflux and cancer.
    Turcotte S; Duranceau A
    Thorac Surg Clin; 2005 Aug; 15(3):341-52. PubMed ID: 16104125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sequential model of Barrett's esophagus and adenocarcinoma induced by duodeno-esophageal reflux without exogenous carcinogens.
    Sato T; Miwa K; Sahara H; Segawa M; Hattori T
    Anticancer Res; 2002; 22(1A):39-44. PubMed ID: 12017320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Classification System to Identify High-Grade Dysplasia and Esophageal Adenocarcinoma in Barrett's Esophagus Using Narrow-Band Imaging.
    Sharma P; Bergman JJ; Goda K; Kato M; Messmann H; Alsop BR; Gupta N; Vennalaganti P; Hall M; Konda V; Koons A; Penner O; Goldblum JR; Waxman I
    Gastroenterology; 2016 Mar; 150(3):591-8. PubMed ID: 26627609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging endoscopic techniques for the identification of esophageal disease.
    Triadafilopoulos G; Akiyama J
    Expert Rev Gastroenterol Hepatol; 2016; 10(5):605-13. PubMed ID: 26753504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenocarcinoma and Barrett's esophagus following surgically treated achalasia.
    Shah AN; Gunby TC
    Gastrointest Endosc; 1984 Oct; 30(5):294-6. PubMed ID: 6489712
    [No Abstract]   [Full Text] [Related]  

  • 18. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
    Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
    Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis.
    Arcidiacono D; Antonello A; Fassan M; Nucci D; Morbin T; Agostini M; Nitti D; Rugge M; Alberti A; Battaglia G; Realdon S
    Dig Liver Dis; 2017 Jun; 49(6):630-638. PubMed ID: 28185837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.